

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



ASCENTAGE PHARMA GROUP INTERNATIONAL
亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6855)

SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING

Reference is made to the notice dated April 16, 2025 (the “**Original AGM Notice**”) in relation to the AGM of Ascentage Pharma Group International (the “**Company**”) to be held at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China on May 19, 2025 at 10:00 a.m. and the resolutions to be proposed at the AGM for the Shareholders’ approval. Unless otherwise defined, capitalized terms used in this supplemental notice (the “**Supplemental AGM Notice**”) shall have the same meanings as those defined in the supplemental circular of the Company dated April 30, 2025 (the “**Supplemental Circular**”).

Details of resolutions Nos. 1 to 7 (inclusive) to be considered at the AGM are stated in the Original AGM Notice. Save for the additional resolution set out below, all information contained in the Original AGM Notice remains valid and unchanged.

SUPPLEMENTAL NOTICE IS HEREBY GIVEN THAT the AGM of the Company will be held as originally scheduled at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China on May 19, 2025 at 10:00 a.m. to, among others, consider and, if thought fit, pass the following additional resolutions.

ORDINARY RESOLUTIONS

8. To consider and, if thought fit, pass (with or without amendments), the following resolution as an ordinary resolution that: the proposed amendments to the 2021 RSU Scheme be and are hereby approved and confirmed.
9. To consider and, if thought fit, pass (with or without amendments), the following resolution as an ordinary resolution that: the proposed amendments to the 2022 RSU Scheme be and are hereby approved and confirmed.
10. To consider and, if thought fit, pass (with or without amendments), the following resolution as an ordinary resolution that: the proposed amendments to the Post IPO Share Option Scheme be and are hereby approved and confirmed.

11. To consider and, if thought fit, pass (with or without amendments), the following resolution as an ordinary resolution that: the Scheme Mandate Limit on the total number of Shares that may be issued in respect of all options and awards to the eligible participants under all the Share Schemes of the Company be and is hereby approved and confirmed.
12. Conditional upon the passing of the ordinary resolution numbered 11, to consider and, if thought fit, pass (with or without amendments), the following resolution as an ordinary resolution that: the Service Provider Sublimit on the total number of Shares that may be issued in respect of all options and awards to be granted to the Service Providers under all the Share Schemes of the Company be and is hereby approved and confirmed.

By Order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, The People's Republic of China, April 30, 2025

Notes:

1. Save for the inclusion of the additional proposed resolutions set out in this Supplemental AGM Notice (Nos. 8 to 12), there are no other changes to the Original Notice. For details of resolutions Nos. 1 to 7 to be considered at the AGM, closure of the register of members of the Company, eligibility for attending the AGM, appointment of proxy and other relevant matters, please refer to the Original AGM Notice.
2. Shareholders are advised to read the Circular issued by the Company on April 16, 2025 and the Supplemental Circular to the Shareholders issued on April 30, 2025 which contain detailed information concerning the resolutions to be considered at the AGM.
3. The Second Proxy Form
 - (1) The new proxy form for the AGM (the “**Second Proxy Form**”), which supersedes the first proxy form for use at the AGM issued along with the Original AGM Notice on April 16, 2025 (the “**First Proxy Form**”), has been prepared and is enclosed with this Supplemental AGM Notice.
 - (2) Whether or not you are able to attend the AGM, you are requested to complete the accompanying Second Proxy Form in accordance with the instructions printed thereon and return it to the Company’s Hong Kong Branch Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, or via the designated URL (<https://evoting.vistra.com/>) by using the username and password provided on the notification letter sent by the Company as soon as possible but in any event not less than 48 hours before the time appointed for the holding of the AGM (i.e. not later than 10:00 a.m. on May 17, 2025) or the adjourned meeting (as the case may be) (the “**Closing Time**”). Completion and return of the Second Proxy Form will not preclude the shareholders of the Company from attending and voting in person at the AGM or any adjournment thereof.
 - (3) Shareholder who has not yet lodged the First Proxy Form with the Company’s Hong Kong Branch Share Registrar is requested to lodge the Second Proxy Form if he/she wishes to appoint a proxy to attend the AGM on his/her behalf. In this case, the First Proxy Form should not be lodged with the Company’s Hong Kong Branch Share Registrar.
 - (4) Shareholder who has already lodged the First Proxy Form with the Company’s Hong Kong Branch Share Registrar should note that:
 - (i) the Second Proxy Form lodged with the Company’s Hong Kong Branch Share Registrar before the Closing Time will revoke and supersede the First Proxy Form previously lodged by him/her. The Second Proxy Form will be treated as a valid form of proxy lodged by the shareholder if correctly completed; and
 - (ii) if no Second Proxy Form is lodged with the Company’s Hong Kong Branch Share Registrar, the First Proxy Form will remain valid and effective to the fullest extent applicable if correctly completed. The proxy appointed under the First Proxy Form will also be entitled to vote in accordance with the instructions previously given by the shareholder or at his/her discretion (if no such instructions are given) on any resolution properly put to the AGM including the new resolutions Nos. 8 to 12 which was not set out in the First Proxy Form.

As at the date of this notice, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director; Dr. Wang Shaomeng and Dr. Lu Simon Dazhong as non-executive Directors; and Mr. Ye Changqing, Dr. David Sidransky, Ms. Marina S. Bozilenko, Dr. Debra Yu and Marc E. Lippman, MD as independent non-executive Directors.